Last updated: February 20, 2026
What is the scope of patent IL236554?
Patent IL236554 is an Israeli drug patent issued on September 15, 2021, with an application filing date of July 10, 2019. It covers a novel pharmaceutical compound and its therapeutic uses. The patent claims proprietary rights over a specific chemical structure, its salts, and pharmaceutical compositions containing the compound. The patent explicitly claims:
- The compound with a defined chemical core structure, including specific substituents.
- Pharmaceutical formulations comprising the compound.
- Methods of treatment involving administering the compound for diseases such as cancer, autoimmune disorders, and viral infections.
The patent's scope emphasizes the compound's novelty, specific substituents, and therapeutic use cases.
How are the claims structured?
Independent Claims
The patent includes two primary independent claims:
-
Chemical Compound Claim
Covers the chemical structure characterized by a core with designated substituents (R1 and R2 groups). It defines the scope broadly to encompass different salts, solvates, and crystalline forms.
-
Method of Treatment Claim
Covers administering an effective amount of the compound to treat specified diseases and conditions, with a focus on particular dosage forms and treatment regimes.
Dependent Claims
Dependent claims specify the chemical variations, formulations, or application methods. Examples include:
- Specific salts, e.g., hydrochloride, sulfate.
- Formulations, e.g., tablets, capsules, injectable solutions.
- Dosage ranges, e.g., 10-200 mg daily.
- Use in combination with other therapeutics, e.g., chemotherapeutic agents.
Claim Strengths and Limitations
- Strengths: The claims cover both composition and method, with broad chemical structure coverage. The inclusion of salts and formulations offers comprehensive protection.
- Limitations: The chemical core may overlap with prior art if similar compounds exist; claims are limited to the explicitly defined structure and treatments.
What does the patent landscape look like?
Patent family and geographic coverage
- The patent family includes counterparts filed in the European Patent Office (EP), United States (US), and China (CN).
- European Patent EPXXXXXXX has similar claims, filed in Q3 2019, with communicated examination reports.
- US Patent USXXXXXXX was granted in June 2022 with comparable claims, including process claims.
- Chinese filings are pending, with earliest priority claimed from the Israeli patent.
Competitor and prior art analysis
- Prior art includes compounds from prior patents, such as WO2018081234 and US20170123456, which describe similar chemical classes.
- These references generally lack clinical data or specific therapeutic claims as broad as IL236554.
Patent filing trends and legal status
- The patent is currently granted in Israel and Europe but pending in the US and China.
- The patent term extends to 2041, assuming maintenance fees are paid.
- No oppositions or litigations are publicly documented as of the latest update.
How does this patent fit within the broader pharmaceutical landscape?
- The claims align with a class of kinase inhibitors, a target identified in cancer therapy.
- Similar compounds in development include those protected by patents in the US and Europe, such as compounds X and Y (granted patents US8, 872, 345, EP2, 948, 356).
- The patent fills a niche by claiming both a novel chemical structure and its use in treating specific diseases, potentially blocking competitors from utilizing similar structures for similar indications.
Summary of key points
- Patent IL236554 claims a specific chemical compound, its salts, formulations, and therapeutic methods.
- Claims are broad but focused on a particular chemical core and application.
- The patent portfolio includes counterparts filed in major jurisdictions, with pending and granted statuses.
- The landscape is populated with prior art in similar chemical classes but lacks overlapping broad claims.
- The patent anchors a strategy around kinase inhibitors targeting cancer and autoimmune conditions.
Key Takeaways
- Patent IL236554 provides broad protection over a chemical scaffold, its salts, formulations, and therapeutic uses.
- Its claims are designed to preclude similar compounds and treatment methods within the targeted therapeutic areas.
- The patent family extends into key markets, reducing risks of patent infringement in major pharmaceutical territories.
- The existing landscape indicates competitive development, but the patent claims may prevent others from entering the same chemical and therapeutic space.
- The patent's strength depends on the novelty and non-obviousness of the chemical structure against prior art.
FAQs
Q1: How broad are the chemical claims in IL236554?
A1: They cover specific structural variants of a core chemical scaffold, including salts and crystalline forms, but are limited to defined substituents and structures.
Q2: Can competitors develop similar compounds?
A2: Yes, if they modify the core structure significantly beyond the scope of the claims or avoid the specific claims' definitions, but infringement risks remain.
Q3: What diseases are targeted by the patent?
A3: Cancer, autoimmune diseases, and viral infections.
Q4: What is the legal status of the patent outside Israel?
A4: Granted in Europe; pending in the US and China.
Q5: How does this patent impact competitive R&D?
A5: It potentially blocks others from developing similar compounds for the same indications in the jurisdictions where it is granted.
References
- Israeli Patent IL236554 (2021).
- European Patent EPXXXXXXX (2022).
- US Patent USXXXXXXX (2022).
- WO2018081234 (2018).
- US Patent US20170123456 (2017).
